959162-97-1 Usage
General Description
Ethyl 6-chloro-4-(ethylamino)nicotinate is a chemical compound that belongs to the class of nicotinic acid esters. It is a derivative of nicotine and is often used in the pharmaceutical industry for its potential therapeutic properties. The chemical structure of ethyl 6-chloro-4-(ethylamino)nicotinate consists of an ethyl group, a chloro group, and an ethylamino group attached to a nicotinate moiety. ethyl 6-chloro-4-(ethylamino)nicotinate is known to have potential use as an antiviral, anti-inflammatory, and analgesic agent, and its properties are being investigated for various medical applications. Ethyl 6-chloro-4-(ethylamino)nicotinate is a subject of ongoing research and may hold promise for the development of new drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 959162-97-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,9,1,6 and 2 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 959162-97:
(8*9)+(7*5)+(6*9)+(5*1)+(4*6)+(3*2)+(2*9)+(1*7)=221
221 % 10 = 1
So 959162-97-1 is a valid CAS Registry Number.
959162-97-1Relevant articles and documents
GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS
-
Page/Page column 38, (2021/05/15)
The present invention relates to certain gem-disubstituted heterocyclic compounds, which modulate the activity of Isocitrate Dehydrogenase (IDH). The compounds of this invention are therefore useful in treating diseases caused by mutated IDH1 and/or mutat
HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS
-
Page/Page column 49; 51, (2019/12/15)
The present invention relates to certain substituted heterocondensed pyridone analogues of formula (I) which modulate the activity of Isocitrate Dehydrogenase (IDH). The compounds of this invention are therefore useful in treating diseases caused by mutat
INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
-
Paragraph 0153; 0154; 0155, (2015/07/22)
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.